Important new paper. Continued lecanemab exposure “improves” amyloid-associated biomarkers while some neuronal/synaptic biomarkers move progressively farther from normal. A team led by Carlos… | Albe...

The “Early is Better” Alzheimer’s mantra is challenged by the evidence. For years, a standard explanation for failed anti-amyloid trials has been: “We treated patients too late.” The reasoning was… ...

#alzheimers #lecanemab | Alberto Espay

Less tau accumulation. More clinical deterioration. The PROSPECT-ALZ trial of the OGA* inhibitor ceperognastat offers another striking example of biomarker–clinical dissociation in Alzheimer’s… | Alb...

In the new world of blood-based biomarkers, what is a positive p-tau217 accurate for? A positive p-tau217 is highly accurate for identifying the presence of amyloid and tau pathology in the brain… | ...

#alzheimersdisease #lecanemab #donanemab | Alberto Espay

#alzheimersdisease #lecanemab #donanemab | Alberto Espay

A perfect Sunday conversation. One enlightened colleague earlier today brought up one of the greatest dramas in the history of medicine: the once crazy suggestion that gastric ulcers might be caused… ...

Clinical Heterogeneity in Orthostatic Movement Disorders: Insights from Latent Class Analysis and Disease Burden Scoring

What Does α-Syn-SAA-Negative Parkinson's Disease Reveal About the Proposed “Biological Definition” of Parkinson's Disease? An analysis of the PPMI cohort found remarkably few differences betw...

On this day in 1633, Galileo was forced to recant his support for the Copernican view that the Earth was not the center of the universe. For his heresy, the church sentenced him to life imprisonment… ...

The house of cards we built around α-synuclein as the biological definition and toxic driver of Parkinson’s disease is unraveling from the inside, suggests a new analysis from the PPMI study, just… | ...

#alzheimers | Alberto Espay

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease | Biogen | Alberto Esp...

#alzheimers #tau | Alberto Espay | 23 comments

I now understand why we can look at the same data on tests of pathology and come to very different conclusions. Some see blood-based biomarkers like high pTau217 and conclude: “We can now detect… | A...

A 56-year-old man presents with parkinsonism. Brain imaging reveals basal ganglia calcifications. His clinician, concluding that the calcifications triggered his symptoms, prescribes calcium… | Albert...

Statins for primary cardiovascular prevention in Parkinson’s disease: is it time to rethink the balance of risk and benefit? A new study adds to the concern that statins may not be benign in PD. In… ...

If Parkinson’s is “biologically defined” by a positive α-synuclein test, what do we do with the 10% who are negative? The α-synuclein seed amplification assay (αsyn-SAA) sensitively detects… | Alberto...

Science For Sale: How Drugmakers Captured The FDA | Alberto Espay

𝐓𝐡𝐢𝐬 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐰𝐢𝐥𝐥 𝐬𝐡𝐫𝐢𝐧𝐤 𝐲𝐨𝐮𝐫 𝐛𝐫𝐚𝐢𝐧. 𝐘𝐨𝐮'𝐫𝐞 𝐰𝐞𝐥𝐜𝐨𝐦𝐞. That statement is not rhetorical. We are told that reduced brain volume is the mechanism by which… | Alberto Espay

Parkinson’s disease is often framed as a disorder of 'toxic accumulation' of pathological α-synuclein. Yet the reciprocal process, the depletion of soluble, functional α-synuclein, has receive...

Alzheimer’s Isn’t Inevitable - What Top Harvard Scientist Now Knows About Prevention

Detecting Alzheimer’s — or Detecting Age?

Resolving the Biomarker-Clinical “Mismatch” in Alzheimer's Disease

Valacyclovir Treatment of Early Symptomatic Alzheimer Disease

Why the latest test for Parkinson’s cannot be quantitative –only binary (yes/no)

Restoring amyloid-β42 and γ-secretase function in Alzheimer’s disease

A Biomarker‐Based Classification of Corticobasal Syndrome

Beyond Pathology: α‐Synuclein Homeostasis and Three Principles to Guide Research

Clinical and MRI Correlates of β‐Amyloid Load Inconsistent With Its Presumed Neurotoxicity in Cognitively Healthy Ageing

‘Pathology is disease’ Parkinson's mythology: The ‘brain-first-body-first’ case study - Alberto J. Espay, Andrew J. Lees, 2025

Sage Journals: Discover world-class research

A mind-reading brain implant that comes with password protection

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP) | Amylyx Pharmaceuticals, Inc.

Restoring amyloid-β42 and γ-secretase function in Alzheimer’s disease

What counts as plagiarism? AI-generated papers pose new risks

Phosphorylated α-synuclein in CSF and plasma does not reflect synucleinopathy - npj Parkinson's Disease

Copper supplementation mitigates Parkinson-like wild-type SOD1 pathology and nigrostriatal degeneration in a novel mouse model - Acta Neuropathologica Communications

Education and Accelerated Tau Accumulation in Alzheimer Disease

BioEssays: Physics of Protein Aggregation in Normal and Accelerated Brain Aging